TRIM33 and cancer: A systematic review of 6 studies including 312 patients with DM showed that the sensitivity and specificity of anti-TIF-1γ antibodies for diagnosing cancer-associated DM in 66 patients (21.2%) were 78% (95% CI 45–94%) and 89% (95% CI 82–93%), respectively [30].